Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Director | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orchestra BioMed Holdings, Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 54,750 |
Reported balance
After 2026-08-12 transaction · row 1
1 source rowRow 1 · 2026-08-12 · Tax withholding · Disposed 3,761 · Balance 54,750 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVANOS MEDICAL, INC.
Report date July 27, 2026 · Filed July 28, 2026
Section 16 reporting ended · disclosed 2026-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-27 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-27 · Disposition to issuer · Disposed 322,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement. F2: Includes 270,774 restricted stock units of the Company which were subject to only time-based vesting conditions (each, a Company TRSU). Pursuant to the Merger Agreement, these Company TRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration by (ii) the number of shares of Common Stock the reporting person would have been entitled to receive if such Company TRSUs had vested in full (less applicable tax withholdings) Row 2 · 2026-07-27 · Grant · Acquired 444,730 · Balance 444,730 F3: Represents the deemed acquisition and disposition of Common Stock pursuant to restricted stock units that were subject to performance-based vesting conditions (each, a Company PRSU), which were previously granted to the reporting person. F4: Pursuant to the Merger Agreement, these Company PRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration per share of Common Stock by (ii) the number of shares of Common Stock such holder would have been entitled to receive if such Company PRSU award had vested based on (A) actual performance against performance metrics for any one-year performance period completed prior to the Effective Time, (B) for any one-year performance period that is in progress as of the Effective Time, the greater of (1) actual achievement against performance metrics and (2) its target level (although, as referenced below, such awards will be converted at target level with a potential true-up), and (C) deemed achievement at target level for any one-year performance period that has not yet commenced as of the Effective Time (less applicable tax withholdings). F5: The amount reported represents the aggregate number of Company PRSUs paid out to the Reporting Person at (or within 15 business days following) the Effective Time based on target performance for fiscal year 2026. In the event that actual performance for fiscal year 2026 exceeds target, the reporting person will receive a true-up payment. The maximum aggregate number of Company PRSUs that the reporting person could earn based on actual performance for fiscal year 2026 is 754,331. Row 3 · 2026-07-27 · Disposition to issuer · Disposed 444,730 · Balance 0 F3: Represents the deemed acquisition and disposition of Common Stock pursuant to restricted stock units that were subject to performance-based vesting conditions (each, a Company PRSU), which were previously granted to the reporting person. F4: Pursuant to the Merger Agreement, these Company PRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration per share of Common Stock by (ii) the number of shares of Common Stock such holder would have been entitled to receive if such Company PRSU award had vested based on (A) actual performance against performance metrics for any one-year performance period completed prior to the Effective Time, (B) for any one-year performance period that is in progress as of the Effective Time, the greater of (1) actual achievement against performance metrics and (2) its target level (although, as referenced below, such awards will be converted at target level with a potential true-up), and (C) deemed achievement at target level for any one-year performance period that has not yet commenced as of the Effective Time (less applicable tax withholdings). F5: The amount reported represents the aggregate number of Company PRSUs paid out to the Reporting Person at (or within 15 business days following) the Effective Time based on target performance for fiscal year 2026. In the event that actual performance for fiscal year 2026 exceeds target, the reporting person will receive a true-up payment. The maximum aggregate number of Company PRSUs that the reporting person could earn based on actual performance for fiscal year 2026 is 754,331. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.69 · Expires 2036-03-13 | Direct | 0 |
Reported balance
After 2026-07-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-27 · Disposition to issuer · Disposed 239,354 · Balance 0 F7: Pursuant to the Merger Agreement, these stock options were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the excess of (A) the Merger Consideration minus (B) the exercise price payable in respect of each share of Common Stock subject to such stock option, by (ii) the number of shares of Common Stock the reporting person would have been entitled to receive upon exercise if such stock option award had vested in full (less applicable tax withholdings). Company stock options with an exercise price per share that exceeds the Merger Consideration were canceled for no consideration, which cancelations are exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rules 16a-4(d) and 16b-6(d) thereunder. F6: These options were originally scheduled to vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
F2: Includes 270,774 restricted stock units of the Company which were subject to only time-based vesting conditions (each, a Company TRSU). Pursuant to the Merger Agreement, these Company TRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration by (ii) the number of shares of Common Stock the reporting person would have been entitled to receive if such Company TRSUs had vested in full (less applicable tax withholdings)
F3: Represents the deemed acquisition and disposition of Common Stock pursuant to restricted stock units that were subject to performance-based vesting conditions (each, a Company PRSU), which were previously granted to the reporting person.
F4: Pursuant to the Merger Agreement, these Company PRSUs were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the Merger Consideration per share of Common Stock by (ii) the number of shares of Common Stock such holder would have been entitled to receive if such Company PRSU award had vested based on (A) actual performance against performance metrics for any one-year performance period completed prior to the Effective Time, (B) for any one-year performance period that is in progress as of the Effective Time, the greater of (1) actual achievement against performance metrics and (2) its target level (although, as referenced below, such awards will be converted at target level with a potential true-up), and (C) deemed achievement at target level for any one-year performance period that has not yet commenced as of the Effective Time (less applicable tax withholdings).
F5: The amount reported represents the aggregate number of Company PRSUs paid out to the Reporting Person at (or within 15 business days following) the Effective Time based on target performance for fiscal year 2026. In the event that actual performance for fiscal year 2026 exceeds target, the reporting person will receive a true-up payment. The maximum aggregate number of Company PRSUs that the reporting person could earn based on actual performance for fiscal year 2026 is 754,331.
F6: These options were originally scheduled to vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.
F7: Pursuant to the Merger Agreement, these stock options were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying (i) the excess of (A) the Merger Consideration minus (B) the exercise price payable in respect of each share of Common Stock subject to such stock option, by (ii) the number of shares of Common Stock the reporting person would have been entitled to receive upon exercise if such stock option award had vested in full (less applicable tax withholdings). Company stock options with an exercise price per share that exceeds the Merger Consideration were canceled for no consideration, which cancelations are exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rules 16a-4(d) and 16b-6(d) thereunder.
Apollo Endosurgery, Inc.
Report date April 04, 2023 · Filed April 04, 2023
Section 16 reporting ended · disclosed 2023-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-04 transaction · row 1
1 source rowRow 1 · 2023-04-04 · Disposition to issuer · Disposed 18,112 · Balance 0 F1: Reflects the disposition of the reporting person's 3,888 shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions. F2: Reflects the disposition of the reporting person's 14,224 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.98 · Expires 2027-12-12 | Direct | 0 |
Reported balance
After 2023-04-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-04 · Disposition to issuer · Disposed 15,154 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2023-04-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-04-04 · Disposition to issuer · Disposed 19,333 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2029-08-16 | Direct | 0 |
Reported balance
After 2023-04-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-04 · Disposition to issuer · Disposed 16,536 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2030-05-07 | Direct | 0 |
Reported balance
After 2023-04-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-04 · Disposition to issuer · Disposed 27,749 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.86 · Expires 2031-06-17 | Direct | 0 |
Reported balance
After 2023-04-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-04 · Disposition to issuer · Disposed 5,271 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's 3,888 shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions.
F2: Reflects the disposition of the reporting person's 14,224 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the "inducement" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the "Issuer Stock Plans", and each such option, an "Issuer Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 3,400 | $6.92 | $23,528.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 14 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 5,524 | $6.91 | $38,170.84 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 13 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,790 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 3,144 | $6.90 | $21,693.60 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 12 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,314 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 464 | $6.89 | $3,196.96 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 11 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,458 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 1,100 | $6.88 | $7,568.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 10 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,922 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 20 | $6.85 | $137.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 9 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,022 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 500 | $6.81 | $3,405.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 8 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,042 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 600 | $6.80 | $4,080.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 7 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,542 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 600 | $6.73 | $4,038.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 6 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,142 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 300 | $6.72 | $2,016.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 5 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,742 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 100 | $6.71 | $671.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 4 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,042 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 800 | $6.70 | $5,360.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 3 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,142 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 200 | $6.67 | $1,334.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 2 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,942 Read SEC document |
| May 19, 2021 Filed May 20, 2021 17:50 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | SaleCommon Stock | 600 | $6.64 | $3,984.00 |
DisclosureSEC source: 0001251769-21-000068 · wf-form4_162154738122636.xml · nonDerivative · entry 1 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,142 Read SEC document |
| May 07, 2020 Filed May 11, 2020 17:32 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,749 | $2.08 Strike: $2.08 | $57,717.92 |
DisclosureSEC source: 0001251769-20-000055 · wf-form4_158923276040346.xml · derivative · entry 2 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,439 Underlying: Common Stock · 27,749 shares Expires 2030-05-07 F2 · date: The shares underlying the option shall vest fully on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the option shall vest fully on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. Read SEC document |
| May 07, 2020 Filed May 11, 2020 17:32 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantCommon Stock | 10,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001251769-20-000055 · wf-form4_158923276040346.xml · nonDerivative · entry 1 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,742 F1 · date: Represents the grant of Restricted Stock Units ("RSU"). Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock pursuant to the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. The RSUs vest fully on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Incentive Plan. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 16:33 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 0 | $3.27 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001251769-19-000080 · wf-form4_156633321405738.xml · derivative · entry 2 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,690 Underlying: Common Stock · 16,536 shares Expires 2029-08-16 F1 · derivative.exercise_price: Fully vested at one year anniversary of grant date. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 16:33 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantCommon Stock | 5,399 | $3.27 | $17,654.73 |
DisclosureSEC source: 0001251769-19-000080 · wf-form4_156633321405738.xml · nonDerivative · entry 1 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,736 F1 · date: Fully vested at one year anniversary of grant date. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 17:27 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantStock Option (Right to Buy) · Derivative | 15,154 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001251769-17-000085 · wf-form4_151320405275293.xml · derivative · entry 2 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,154 Underlying: Common Sock · 15,154 shares Expires 2027-12-12 F1 · security: Award is issued pursuant to the 2017 Equity Incentive Plan. F3 · derivative.exercise_date: 1/12th of the shares subject to the option will vest on each one-month anniversary of December 12, 2017. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 17:27 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | GrantCommon Sock | 3,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001251769-17-000085 · wf-form4_151320405275293.xml · nonDerivative · entry 1 Pacitti David · CIK 0001722733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,337 F1 · security: Award is issued pursuant to the 2017 Equity Incentive Plan. F2 · shares: 1/12th of the shares will vest on each one-month anniversary of December 12, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.